Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa in metastatic colorectal cancer
NCT00233623Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gefitinib in metastatic colorectal cancer (mCRC), sponsored by AstraZeneca. Primary endpoint: Time to progression. Planned start Jul 2004; status: withdrawn.
02
Drugs
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00233623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233623.